In our study, we showed a decrease in the cMYC expression level (37.56% ± 8.16 vs. 100% ± 9.12; p < 0.05) and protein level (0.725 ± 0.003 ng/mL vs. 1.122 ± 0.003 ng/mL; p = 0.058) in patients with ovarian cancer compared to the control group from Poland. Here, MYC is linked to ovarian cancer.